The U.S. government has released its 2026 Medicare Advantage and prescription drug plan quality ratings, offering insight into how major health insurers performed in providing care to seniors. These annual ratings, issued by the Centers for Medicare & Medicaid Services (CMS), play a key role in determining bonus payments to insurers—worth hundreds of millions or even billions of dollars—and influence plan revenues in 2027.
According to CMS data, CVS Health’s Aetna stands out with over 81% of members enrolled in top-rated plans, while UnitedHealth Group follows closely with 78%. Elevance Health improved significantly, reaching 55% of members in 4-star or higher plans, compared to 40% last year. In contrast, Humana saw only about 20%, or 1.2 million members, in highly rated plans.
Overall, 64% of all Medicare Advantage members with prescription drug coverage are enrolled in plans rated four stars or higher, according to Oppenheimer analysts. These ratings assess factors such as customer satisfaction, access to care, chronic disease management, and preventive health screenings, ensuring seniors can make informed choices when selecting coverage.
CVS Health said more than 63% of its Aetna Medicare Advantage members are in 4.5-star plans for next year. Meanwhile, UnitedHealth reported that 40% of its members are enrolled in 4.5-star or higher plans, consistent with its earlier projections. Analysts described this year’s results as largely expected, following recent company updates.
Centene’s Wellcare, led by CEO Michael Carson, also reported continued improvement, emphasizing the company’s focus on delivering high-quality, affordable healthcare and enhancing health outcomes nationwide.
As competition intensifies, star ratings continue to shape the landscape of the Medicare Advantage market, rewarding insurers that excel in quality and member satisfaction while motivating others to raise their standards.


Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 



